{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:10:43Z","timestamp":1792807843153,"version":"4.5.0"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,3,15]]},"DOI":"10.2169\/internalmedicine.5834-25","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T22:08:17Z","timestamp":1755727697000},"page":"788-794","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Dotinurad in Patients with Advanced Chronic Kidney Disease"],"prefix":"10.2169","volume":"65","author":[{"given":"Teppei","family":"Motomura","sequence":"first","affiliation":[{"name":"Department of Nephrology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuka","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirayasu","family":"Kai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Japan"},{"name":"Ibaraki Clinical Education and Training Center, University of Tsukuba Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Storhaug HM, Norvik JV, Toft I, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Troms\u00f8 Study. BMC Cardiovasc Disord 13: 115, 2013.","DOI":"10.1186\/1471-2261-13-115"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 61: 225-232, 2009.","DOI":"10.1002\/art.24164"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Takae K, Nagata M, Hata J, et al. Serum uric acid as a risk factor for chronic kidney disease in a Japanese community - The Hisayama Study -. Circ J 80: 1857-1862, 2016.","DOI":"10.1253\/circj.CJ-16-0030"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hosoya T, Ohno I, Nomura S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol 18: 876-884, 2014.","DOI":"10.1007\/s10157-014-0935-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res 37: 919-925, 2014.","DOI":"10.1038\/hr.2014.107"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clin Exp Nephrol 24 (Suppl 1): 53-61, 2020.","DOI":"10.1007\/s10157-019-01818-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. Clin Exp Nephrol 24 (Suppl 1): 62-70, 2020.","DOI":"10.1007\/s10157-020-01849-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hosoya T, Fushimi M, Okui D, Sasaki T, Ohashi T. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout. Clin Exp Nephrol 24 (Suppl 1): 80-91, 2020.","DOI":"10.1007\/s10157-019-01831-5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Amano H, Kobayashi S, Terawaki H. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease. BMC Nephrol 25: 97, 2024.","DOI":"10.1186\/s12882-024-03535-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yanai K, Hirai K, Kaneko S, et al. The efficacy and safety of dotinurad on uric acid and renal function in patients with hyperuricemia and advanced chronic kidney disease: a single center, retrospective analysis. Drug Des Devel Ther 17: 3233-3248, 2023.","DOI":"10.2147\/DDDT.S416025"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kurihara O, Yamada T, Kato K, Miyauchi Y. Efficacy of dotinurad in patients with severe renal dysfunction. Clin Exp Nephrol 28: 208-216, 2024.","DOI":"10.1007\/s10157-023-02419-w"},{"key":"12","unstructured":"12. Yamazaki T. Effect of dotinurad on serum uric acid levels and renal function in hyperuricemia patients with reduced renal excretion of uric acid. Tsufu To Nyosan, Kakusan (Gout Uric Nucleic Acids) 48: 105-114, 2024 (in Japanese) (Abstract in English)."},{"key":"13","unstructured":"13. Shimazu K, Saibara N, Hama Y, Kitagawa S. Study on the efficacy and safety of dotinurad in patients with hyperuricemia by GFR classification (study by GFR classification): a retrospective observational study. Shinryo-to-shinyaku (Med Consult New Remed) 61: 689-700, 2024 (in Japanese) (Abstract in English)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Takata T, Taniguchi S, Mae Y, et al. Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia. Sci Rep 15: 8990, 2025.","DOI":"10.1038\/s41598-025-94020-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tanabe K, Nunoue T, Itabashi N, et al. Dotinurad treatment for patients with hyperuricemia complicating CKD. Kidney Int Rep 10: 1711-1720, 2025.","DOI":"10.1016\/j.ekir.2025.03.047"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBDCKD Collaboration","year":"2020","unstructured":"17. Collaboration GBDCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395: 709-733, 2020.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"18","unstructured":"18. Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72: 798-810, 2018."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382: 2504-2513, 2020.","DOI":"10.1056\/NEJMoa1915833"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J 40: 1778-1786, 2019.","DOI":"10.1093\/eurheartj\/ehz119"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Takada T, Yamamoto T, Matsuo H, et al. Identification of ABCG2 as an exporter of uremic toxin indoxyl sulfate in mice and as a crucial factor influencing CKD progression. Sci Rep 8: 11147, 2018.","DOI":"10.1038\/s41598-018-29208-w"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Takkavatakarn K, Phannajit J, Udomkarnjananun S, et al. Association between indoxyl sulfate and dialysis initiation and cardiac outcomes in chronic kidney disease patients. Int J Nephrol Renovasc Dis 15: 115-126, 2022.","DOI":"10.2147\/IJNRD.S354658"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci 22: 2021.","DOI":"10.3390\/ijms22179221"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sellmayr M, Hernandez Petzsche MR, Ma Q, et al. Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J Am Soc Nephrol 31: 2773-2792, 2020.","DOI":"10.1681\/ASN.2020040523"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Asahina Y, Sakaguchi Y, Oka T, et al. Association between urinary uric acid excretion and kidney outcome in patients with CKD. Sci Rep 14: 5119, 2024.","DOI":"10.1038\/s41598-024-55809-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Stack AG, Dronamraju N, Parkinson J, et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial. Am J Kidney Dis 77: 481-489, 2021.","DOI":"10.1053\/j.ajkd.2020.09.009"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Grams ME, Sang Y, Ballew SH, et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. J Am Soc Nephrol 30: 1746-1755, 2019.","DOI":"10.1681\/ASN.2019010008"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/6\/65_5834-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:33:14Z","timestamp":1774063994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/6\/65_5834-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5834-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"article-number":"5834-25"}}